[go: up one dir, main page]

Choudhury et al. - Google Patents

Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways

Choudhury et al.

View PDF
Document ID
7657436705183075383
Author
Choudhury B
Ferrara N

External Links

Snippet

Results ManN promotes EC proliferation. We screened a library of 619 highly purified metabolites encompassing a broad spectrum of chemical entities for their ability to affect growth of bovine choroidal microvascular EC (BCEC), in the presence or in the absence of …
Continue reading at flore.unifi.it (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P-C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids

Similar Documents

Publication Publication Date Title
Zhong et al. Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways
Newman et al. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside
Hsu et al. Effects of WSG, a polysaccharide from Ganoderma lucidum, on suppressing cell growth and mobility of lung cancer
US20120264928A1 (en) Therapeutic pharmaceutical agent for diseases associated with decrease in function of gne protein, food composition, and food additive
EP3060204B1 (en) Beta-catenin
Ilkhanizadeh et al. Antisecretory factor–mediated inhibition of cell volume dynamics produces antitumor activity in glioblastoma
Aizawa et al. Lactoferrin promotes autophagy via AMP-activated protein kinase activation through low-density lipoprotein receptor-related protein 1
Zhu et al. LW-213 induces immunogenic tumor cell death via ER stress mediated by lysosomal TRPML1
WO2017123046A1 (en) Biomarker protein for diagnosing keloid skin or keloid scars, and use thereof
US20230390315A1 (en) Compositions and methods for treating ischemic conditions
US20250295643A1 (en) Methods of treating epilepsy
Takeuchi et al. N-acetylglucosamine suppresses osteoclastogenesis in part through the promotion of O-GlcNAcylation
Choudhury et al. Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways
US20250275993A1 (en) Glycosylation inhibitors as therapeutics for stroke
US6750208B1 (en) Medicine for treating apoptosis dysfunction containing oligosaccharides
WO2020036371A1 (en) Composition for preventing or treating nerve damage disorders comprising grp75 as active ingredient
KR102414285B1 (en) Pharmaceutical composition for prevention or treatment of bone disease containing Flunarizine or pharmaceutically acceptable salts thereof as an active ingredient
US20210386783A1 (en) Use of glucosylceramide synthase gene-deficient t cell and therapeutic utilization thereof
Haxho Role of Neuraminidase-1 in Cancer Development and Clinical Implications
Taneja Understanding the Role of Receptor for Advanced Glycation Endproducts (RAGE) in Pancreatic Cancer and Melanoma
KR20240054851A (en) Composition for improving, preventing or treating of peritoneal fibrosis comprising Tiplaxtinin
Qorri Investigating the Therapeutic Efficacy of Aspirin and Oseltamivir Phosphate in Combination with Gemcitabine for the Treatment of Pancreatic Cancer
Desantis et al. Differential expression of glycans in the urothelial layers of horse urinary bladder
WO2025187114A1 (en) Human breast cancer mda-mb-231 cell proliferation inhibitor
Santana EGFR Glycosylation in Cancer